Optimization of Diagnostic Elisa - Based Tests for the Detection of Auto-Antibodies Against Tumor Antigens in Human Serum

  • Daria Štefatić Division of Oncology, Department of Internal Medicine, Medical University of Graz Institute of Molecular Biosciences, Faculty of Natural Sciences, University of Graz
  • Monika Riederer Division of Oncology, Department of Internal Medicine, Medical University of Graz Institute of Molecular Biology and Biochemistry, Medical University of Graz
  • Marija Balić Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Nadia Dandachi Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Stefanie Stanzer Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Birgit Janesch Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Margit Resel Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Darko Ler Medical University of Graz
  • Hellmut Samonigg Division of Oncology, Department of Internal Medicine, Medical University of Graz
  • Thomas Bauernhofer Division of Oncology, Department of Internal Medicine, Medical University of Graz
Keywords: Auto-antibody, tumor marker, ELISA, colorectal cancer

Abstract

Colorectal cancer is one of the most common cancer types worldwide and it continues to be a serious public health problem. Early detection and diagnosis are of great importance in cancer management. At present, diagnostic blood tests are based on the detection of tumor-associated markers such as carcinoembryonic antigen (CEA), the cancer antigen CA19-9 for gastrointestinal cancer, CA15-3 for breast cancer or CA125 for ovarian cancer. The lack of sensitivity and specificity of these markers prevents their general use in cancer screening of an average risk population. Therefore, new cancer biomarkers or better screening methods are necessary to improve the diagnostics of the disease. This study was directed to the optimization of a diagnostic, enzyme linked immunosorbent assay (ELISA) based test to identify and validate new serum markers, such as extracellular Protein Kinase A (ecPKA) and Nicotinamide A-Meth- yltransferase (NNMT). In this type of assay, the cancer antigens are quantified indirectly - by detecting the presence of auto-antibodies against tumor proteins in human serum. The result of the optimization and validation process was in the case of ecPKA a reproducible and stable assay. In case of NNMT the assay was probably not sensitive enough.

Downloads

Download data is not yet available.
Published
2008-08-20
How to Cite
1.
Štefatić D, Riederer M, Balić M, Dandachi N, Stanzer S, Janesch B, Resel M, Ler D, Samonigg H, Bauernhofer T. Optimization of Diagnostic Elisa - Based Tests for the Detection of Auto-Antibodies Against Tumor Antigens in Human Serum. Bosn J of Basic Med Sci [Internet]. 2008Aug.20 [cited 2019Nov.22];8(3):245-50. Available from: http://www.bjbms.org/ojs/index.php/bjbms/article/view/2926
Section
Immunology